Please login to the form below

Not currently logged in
Email:
Password:

China

This page shows the latest China news and features for those working in and with pharma, biotech and healthcare.

Lynparza cleared for first-line ovarian cancer use in China

Lynparza cleared for first-line ovarian cancer use in China

According to AZ, this approval makes Lynparza the only PARP inhibitor approved in this setting in China. ... area. With this additional approval in China, AZ will likely see the PARP inhibitor grow to an even more solidified blockbuster status.

Latest news

More from news
Approximately 104 fully matching, plus 521 partially matching documents found.

Latest Intelligence

  • Pharmaceutical innovation in the APAC region Pharmaceutical innovation in the APAC region

    We examined these factors for Mainland China, Japan and South Korea, concluding, very broadly:. ... Companies in Mainland China figure most prominently with more than a quarter of the entrants.

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... That does beg the question of how

  • Is anybody listening? Is anybody listening?

    Similarly, authorities in Germany, China, Russia and Australia – as well as the EU in general – are all taking measures to clamp down on companies that aren’t doing enough to fulfil

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December 2018 in China for the treatment of CKD-related anaemia in patients dependent on

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The approach is however also set to be tested as an in vivo therapy for cervical cancer caused by human papillomavirus (HPV) by researchers in China, who are comparing a TALEN ... All told, what is clear is that while He’s experiment has backfired

More from intelligence
Approximately 17 fully matching, plus 111 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 36 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 12 fully matching, plus 57 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics